EFFICIENCY AND PERFORMANCE OF THE USE OF RECOMBINANT INTERFERON GAMMA IN COMPLEX THERAPY OF INFLUENZA A(H1N1)PDM09 PATIENTS
T. V Sologub , A. S Midikari , V. N Agafonov , A. A Suzdalcev , V. V Tsvetkov
Epidemiology and Infectious Diseases ›› 2017, Vol. 22 ›› Issue (2) : 58 -63.
In the period of the epidemic rise in the incidence rate of influenza in 2015-2016 on the basis of infectious hospitals in Simferopol, Arkhangelsk and Samara, there performed a multicenter to evaluate the effectiveness and economic feasibility of two alternative treatment regimens for influenza A (H1N1) pdm09 patients. The study included 88 patients with a laboratory-confirmed diagnosis of influenza A (H1N1)pdm09. Patients of the main group (n = 46) received complex therapy with the use of antiviral (oseltamivir) and immunomodulating (interferon gamma) agents. Patients of the control group (n = 40) received only antiviral therapy (oseltamivir). To assess the effectiveness and economic feasibility of the two different treatment regimens, the outcome of the disease was analyzed: the discharge the hospital up to the 10th day of the illness and no symptoms of the disease by the 3-6th day of treatment. The supplementation of recombinant interferon gamma in the treatment regimen of influenza A (H1N1) pdm09 patients was found to promote the faster release of catarrhal and respiratory symptoms of the disease: the absence of dry cough by the 3-6th day of treatment (RR = 1.43, 95% CI: 0.86 - 2.38), rhinitis (RR 1.21, 95% CI 1.05-1.40) and dyspnea (RR= 1.28, 95% CI: 1.06-1.54). In addition, the supplementation of recombinant interferon gamma in the treatment regimen of patients with influenza A (H1N1)pdm09 promoted a significant shortening of time of the recovery and discharge from the hospital (RR =1.39, 95% CI: 0.97 - 2.00). Clinical and economic analysis of the use of two alternative treatment regimens has shown the supplementation of recombinant interferon gamma in the therapy of influenza A (H1N1) pdm09 patients to be economically favorable
influenza / influenza A (H1N1) pdm09 / influenza treatment / antiviral flu therapy / immunomodulatory therapy for influenza / interferon gamma / Tamiflu / Ingaron
| [1] |
Subramaniam P.S., Torres B.A., Johnson H.M. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine. 2001; 15: 175-87. |
| [2] |
Frucht D.M., Fukao T., Boqdan C., Schindler H., O’shea J.J. et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001; 22: 556-60. |
| [3] |
Adams D.O. Molecular interactions in macrophage activation. Trends Immunol. 1989; 10: 33-5. |
| [4] |
Munder M., Mallo M., Eichmann K., Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 1998; 187: 2103-8. |
| [5] |
Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 2001; 55: 255-81. |
| [6] |
Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J. Leukoc. Biol. 1995; 58: 373-81. |
| [7] |
Bach E.A., Aguet M., Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 1997; 15: 563-91. |
| [8] |
Bot A., Bot S., Bona C.A. Protective role of gamma interferon during the recall response to influenza virus. J. Virol. 1998; 72 (8): 6637-45. |
Eco-vector
/
| 〈 |
|
〉 |
PDF
